Androgen receptor expression and breast cancer survival in postmenopausal women

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1867-1874

  Hu, Rong ^a   Dawood, Shaheenah ^e   Holmes, Michelle D ^a,b   Collins, Laura C ^c   Schnitt, Stuart J ^c   Cole, Kimberley ^c   Marotti, Jonathan D ^c   Hankinson, Susan E ^a,b   Colditz, Graham A ^b,d   Tamimi, Rulla M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUBAI HOSPITAL   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79953315588     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2021     Document Type: Article

References (28)

1. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009;69:6131-40.
2. Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008;8:149.
3. Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol 2009;113:182-8.
4. Soiland H, Korner H, Skaland I, Janssen EA, Gudlaugsson E, Varhaug JE, et al. Prognostic relevance of androgen receptor detection in operable breast cancer. J Surg Oncol 2008;98:551-8.
5. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, et al. Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. Clin Cancer Res 2009;15:2472-8.
6. Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 2006;449:24-30. (Pubitemid 43988362)
7. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120:725-31. (Pubitemid 37339680)
8. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 1984;54:2436-40. (Pubitemid 15223385)
9. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol 2008;4:15-21. (Pubitemid 351372603)
10. Langer M, Kubista E, Schemper M, Spona J. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet 1990;247:203-9. (Pubitemid 20232513)
11. Persijn JP, Korsten CB, Engelsman E. Oestrogen and androgen receptors in breast cancer and response to endocrine therapy. Br Med J 1975;4:503.
12. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010;124:607-17.
13. Sathiakumar N, Delzell E, Abdalla O. Using the National Death Index to obtain underlying cause of death codes. J Occup Environ Med 1998;40:808-13. (Pubitemid 28436140)
14. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol 1994;140:1016-9. (Pubitemid 24373006)
15. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. Am J Epidemiol 1984;119: 837-9. (Pubitemid 14142821)
16. Holmes MD, Murin S, Chen WY, Kroenke CH, Spiegelman D, Colditz GA, et al. (Smoking and survival after breast cancer diagnosis. Int J Cancer 120:2672-7, 2007.
17. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
18. Landis JR, Koch GG. An Application of Hierarchical Kappa-type Statistics in the Assessment of Majority Agreement among Multiple Observers. Biometrics 1977;33:363-374. (Pubitemid 8131514)
19. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 1992;18: 112-8.
20. Kuenen-Boumeester V, Van Der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996;32A:1560-5. (Pubitemid 26279124)
21. Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, et al. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 1979;63: 1271-7. (Pubitemid 10187969)
22. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32. (Pubitemid 46120191)
23. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 2010;29:585-90.
24. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-71. (Pubitemid 41032603)
25. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008. (Pubitemid 43990755)
26. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, et al. : Expression of androgen receptors in primary breast cancer. Ann Oncol 2010;21: 488-92.
27. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 2008; 13:431-5.
28. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.